High Throughput Screening Market Share, Size, Trends, Industry Analysis Report: By Offerings (Consumables, Instruments, Services, Software), By Technology, By Application, By End-User, and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2024-2032
- Published Date:Oct-2024
- Pages: 118
- Format: PDF
- Report ID: PM5087
- Base Year: 2023
- Historical Data: 2019-2022
High Throughput Screening Market Overview
The global high throughput screening market size was valued at USD 29.40 billion in 2023. The industry is projected to grow from USD 32.41 billion in 2024 to USD 74.53 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.0% during the forecast period.
High throughput screening (HTS) is a method widely used in drug discovery and research to quickly test millions of chemicals, genes, or pharmacological agents. Its purpose is to identify active compounds, antibodies, or genes that impact specific biomolecular pathways. This process uses automated systems and advanced software to handle and analyze a large volume of samples efficiently.
The high throughput screening market is experiencing robust growth driven by the increasing prevalence of chronic diseases, and the persistent need for effective treatments have fueled a surge in drug discovery initiatives worldwide. According to the WHO, noncommunicable diseases (NCDs) cause 41 million deaths annually, with 17 million premature deaths occurring mainly in low- and middle-income countries, where cardiovascular diseases account for 17.9 million deaths, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2 million). This raises the demand for high throughput screening tests.
High throughput screening (HTS) has emerged as a key technology in this quest, revolutionizing the speed and efficiency of identifying potential drug candidates. Automating the assessment of extensive libraries of chemical compounds against disease targets, HTS accelerates the early stages of drug discovery.
This capability is particularly crucial in tackling complex diseases where traditional methods would be too slow or labor-intensive.
HTS allows researchers to quickly evaluate thousands to millions of compounds, pinpointing those suitable for further development. This speedy screening process accelerates the discovery of lead compounds and also enhances the likelihood of finding molecules with pharmacological properties. As a result, pharmaceutical companies and research institutions are increasingly investing in HTS technologies to rise their pipelines with new therapeutic candidates. For instance, in February 2022, Bruker's Sierra launched the SPR-32 Pro platform, which enables high-throughput multiplexed assays for precise insights into molecular interactions in drug discovery.
To Understand More About this Research: Request a Free Sample Report
Continuous advancements in robotics, automation, and software have also revolutionized high throughput screening (HTS) platforms, significantly enhancing their efficiency and capabilities. Automating repetitive tasks such as sample handling, compound screening, and data analysis, modern HTS systems optimize workflows and accelerate the evaluation of extensive compound libraries.
Moreover, advancements in software have improved the integration of HTS data with downstream analysis tools, facilitating quicker decision-making in drug discovery and development processes.
High Throughput Screening Market Trends
Rising Demand for Personalized Medicines Drives Market Growth
Market CAGR for high throughput screening is being driven by the shift towards personalized medicine, representing a transformative approach in healthcare, aiming to tailor medical treatments to individual patients based on their unique genetic makeup, environmental exposures, and lifestyle factors. High throughput screening (HTS) is pivotal in this paradigm shift by enabling the rapid identification of biomarkers associated with diseases and treatment responses.
Through HTS, researchers screen large numbers of genetic variants, proteins, and other molecular targets to pinpoint those most relevant to individual patient profiles. This capability enhances understanding of disease mechanisms at a molecular level and also facilitates the development of targeted therapies and personalized medicines through overall process analysis. For instance, in February 2024, SCIEX's Echo MS+ system enhanced high-throughput screening in drug discovery, supporting personalized medicine through precise qualitative and quantitative analysis.
Moreover, HTS supports the discovery and validation of biomarkers that serve as indicators for disease diagnosis, prognosis, and treatment response prediction. By integrating data from HTS with clinical and demographic information, healthcare providers make informed decisions about personalized treatment strategies, optimizing patient outcomes and improving overall healthcare efficiency.
Technological Advancements in Assay Development Drives the Market Demand
Technological advancements in assay development have revolutionized high throughput screening (HTS), making it a cornerstone in pharmaceuticals, biotechnology, and academic research. Miniaturization of assays allows researchers to perform screenings with reduced sample and reagent volumes, significantly lowering costs and increasing throughput. This innovation has streamlined the process of testing large compound libraries against disease targets, accelerating drug discovery timelines. Furthermore, multiplexing technologies enable simultaneous measurement of multiple molecular targets within a single assay, providing comprehensive insights into complex biological processes. This capability is crucial for understanding disease mechanisms and identifying potential therapeutic candidates with higher specificity and efficiency.
High-content screening (HCS) represents another leap forward, combining HTS with advanced imaging and automated analysis techniques. HCS allows researchers to assess cellular morphology, protein localization, and other complex phenotypic characteristics across large-scale assays. These technological advancements collectively expand the scope and capability of HTS, empowering researchers to tackle diverse biomedical challenges and accelerate the development of novel therapies tailored to specific diseases and patient profiles, driving the high throughput screening market revenue.
High Throughput Screening Market Segment Insights
High Throughput Screening Type Insights
The global high throughput screening market segmentation, based on type, includes consumables, instruments, services, and software. The consumables segment held the largest share of the high throughput screening market, primarily due to the widespread use of HTS reagents and assay kits essential throughout the screening process. These consumables require frequent replacement, driving recurring revenue for manufacturers.
The growing demand for HTS consumables supports the overall growth of the market. Some of the factors contributing to this demand include the expansion of pharmaceutical research and development activities and higher government funding for life sciences research and drug discovery and research. For instance, in July 2022, The Council of Scientific and Industrial Research (CSIR) in India made a significant investment of USD 6.73 million in research and development (R&D) activities focused on drug discovery and development.
High Throughput Screening Application Insights
The global high throughput screening market segmentation, based on application, includes drug discovery, biochemical screening, life sciences research, and others. The drug discovery segment dominated the high throughput screening market in 2023, driven by heightened research efforts in drug discovery and development within the pharmaceutical and biotechnology sectors. HTS’s integration with genomics, proteomics, and computational biology enhances its ability to identify and validate drug candidates more effectively.
Additionally, increased support and partnerships from government agencies and research institutions aimed at accelerating drug discovery processes further bolstered growth in this application segment.
High Throughput Screening Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominated the high throughput screening market, driven by a significant increase in research and development and investments by pharmaceutical and biotechnology companies for drug and biomarker development to address the growing prevalence of chronic diseases such as cancer and cardiovascular conditions. According to the International Agency for Research on Cancer, in 2022, there were 20 million new cancer cases and 9.7 million cancer-related deaths worldwide, with projections for 2040 reaching 29.9 million new cases and 15.3 million deaths. Such rising cancer patients in North America drives the market growth of high throughput screening.
Additionally, the region's increased healthcare expenditure supports the adoption of advanced screening technologies, further propelling market growth.
The presence of key market players, including Thermo Fisher Scientific, Agilent Technologies, and Bio-Rad Laboratories, supports North America's position in the HTS market. Furthermore, government initiatives aimed at supporting research and development play a crucial role in fostering an environment conducive to innovation.
The Asia Pacific region is anticipated to be the fastest-growing high throughput screening market during the forecast period, driven by a diverse patient population that embraces a wide range of therapeutics, thereby increasing the demand for unique drug development. Also, the market is driven by rapid growth in the pharmaceutical and biotech industries, increasing investments, cost advantages, supportive government initiatives, and rising disease burden. According to Government of India initiatives and industry projections, in January 2024, India's Pharma-MedTech sector endeavors to enhance its global stature through robust R&D and innovation, aiming to grow the pharmaceutical industry from $50 billion to $120-130 billion and the medical technology sector from $11 billion to $50 billion by 2030.
Additionally, advancements in HTS technologies are improving drug discovery efficiency, making the region a pivotal hub for pharmaceutical innovation.
High Throughput Screening Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the high throughput screening market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the high throughput screening industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global high throughput screening industry to benefit clients and increase the market sector. In recent years, the high throughput screening industry has offered some technological advancements. Major players in the high throughput screening market, including Agilent Technologies, Inc., Aurora Biomed Inc., Axxam S.p.A., Biomat Srl, Bio-Rad Laboratories, Inc., BMG Labtech GmbH, Brand GmbH+Co KG, Charles River Laboratories, Corning Incorporated, Creative Biolabs, Crown Bioscience, Danaher Corporation, DIANA Biotechnologies, A.S., Eppendorf SE, Eurofins Scientific, Gilson Incorporated, Greiner AG, Hamilton Company, HighRes Biosolutions, Lonza, Merck KGaA, Mettler-Toledo International Inc., Porvair Plc, Revvity, Inc., Sartorius AG, Sygnature Discovery Limited, Tecan Group Ltd., Thermo Fisher Scientific Inc., Waters Corporation
Agilent Technologies Inc. Specializes in life sciences, diagnostics, and applied chemical markets, offering a comprehensive array of solutions from instruments and software to services and expertise that address critical challenges and enhance quality of life. In February 2023, Agilent Technologies integrated xCELLigence RTCA HT with BioTek BioSpa 8 Automated Incubator to enhance automation and efficiency in immuno-oncology and vaccine development assays.
Thermo Fisher Scientific Inc. provides services to the scientific community. They are improving patient health via diagnostics, promoting the study of life sciences, resolving complex analytical problems, increasing lab productivity, or creating and producing therapies that will change people's lives. Through their industry-leading brands, which include Thermo Scientific, Invitrogen, Applied Biosystems, Unity Lab Services, Fisher Scientific, Patheon, and PPD. In May 2023, Thermo Fisher Scientific and Pfizer collaborated to expand access to next-generation sequencing-based testing for lung and breast cancer patients in over 30 international markets, aiming to enhance personalized treatment decisions.
Key Companies in the High Throughput Screening market include:
- Agilent Technologies, Inc.
- Aurora Biomed Inc.
- Axxam S.p.A.
- Biomat Srl
- Bio-Rad Laboratories, Inc.
- BMG Labtech GmbH
- Brand GmbH+Co KG
- Charles River Laboratories
- Corning Incorporated
- Creative Biolabs
- Crown Bioscience
- Danaher Corporation
- DIANA Biotechnologies, A.S.
- Eppendorf SE
- Eurofins Scientific
- Gilson Incorporated
- Greiner AG
- Hamilton Company
- HighRes Biosolutions
- Lonza
- Merck KGaA
- Mettler-Toledo International Inc.
- Porvair Plc
- Revvity, Inc.
- Sartorius AG
- Sygnature Discovery Limited
- Tecan Group Ltd.
- Thermo Fisher Scientific Inc.
- Waters Corporation
High Throughput Screening Industry Developments
May 2024: Twist Bioscience launched Twist Multiplexed Gene Fragments (MGFs), enabling high-throughput screening applications with pools of directly synthesized DNA fragments up to 500 base pairs in length.
December 2023: Piramal Pharma expanded its drug discovery capabilities with a new high-throughput screening facility in Ahmedabad, India, enhancing in-vitro biology services for comprehensive client support across research and development.
November 2022: Metrion Biosciences expanded with its new High Throughput Screening (HTS) capability and enlarged facilities in Cambridge, UK, enhancing ion channel drug discovery services for global clients.
High Throughput Screening Market Segmentation:
High Throughput Screening Offerings Outlook
- Consumables
- Reagents & Assay Kits
- Laboratory Consumables
- Instruments
- Liquid Handling Systems
- Detection Systems
- Imaging Systems
- Others
- Services
- Software
High Throughput Screening Technology Outlook
- Cell-based Assays
- 2D Cell Culture
- 3D Cell Culture
- Scaffold-based Technology
- Hydrogels
- Animal-derived Hydrogels
- Matrigel
- Collagen
- Synthetic Hydrogels
- Alginate/Agarose
- Animal-derived Hydrogels
- Inert Matrix/Solid Scaffolds
- Micropatterned Surfaces
- Hydrogels
- Scaffold-free Technology
- Ultra-low Binding Plates
- Hanging-drop Plates
- Others
- Scaffold-based Technology
- Reporter-based Assays
- Perfusion Cell Culture
- Lab-on-a-Chip Technology (LOC)
- Label-free Technology
High Throughput Screening, Application Outlook
- Drug Discovery
- Biochemical Screening
- Life Sciences Research
- Others
High Throughput Screening End-User Outlook
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
- Others
High Throughput Screening Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia-Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
High Throughput Screening Report Scope
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 29.40 billion |
|
Market size value in 2024 |
USD 32.41 billion |
|
Revenue Forecast in 2032 |
USD 74.53 billion |
|
CAGR |
11.0% from 2024 – 2032 |
|
Base Year |
2023 |
|
Historical Data |
2019 – 2022 |
|
Forecast Period |
2024 – 2032 |
|
Quantitative Units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Regional scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global high throughput screening market size was valued at USD 29.40 billion in 2023 and is anticipated to reach at USD 74.53 billion in 2032.
The global market is projected to grow at a CAGR of 11.0% during the forecast period, 2024-2032
North America had the largest share of the global market
The key players in the market are Agilent Technologies, Inc., Aurora Biomed Inc., Axxam S.p.A., Biomat Srl, Bio-Rad Laboratories, Inc., BMG Labtech GmbH, Brand GmbH+Co KG, Charles River Laboratories, Corning Incorporated, Creative Biolabs, Crown Bioscience, Danaher Corporation, DIANA Biotechnologies, A.S., Eppendorf SE, Eurofins Scientific, Gilson Incorporated, Greiner AG, Hamilton Company, HighRes Biosolutions, Lonza, Merck KGaA, Mettler-Toledo International Inc., Porvair Plc, Revvity, Inc., Sartorius AG, Sygnature Discovery Limited, Tecan Group Ltd., Thermo Fisher Scientific Inc., and Waters Corporation.
The consumables category dominated the market in 2023.
The drug discovery had the largest share in the global market.
